Company Profile

Palvella Therapeutics Stock Price, News & Catalysts

Ticker:
PVLA
Exchange:
NASDAQ
Sector:
Biopharma
Location:
Germany

Stock performance

145.77 USD (-0.55%)

Close

Last updated: November 19, 2026

—

Market cap

Why the stock is moving

As of Nov 19, 2026, PVLA closed down 0.55% at $145.77. No new same-company headline was identified in the current news window.

Company overview

Business overview

Pieris was a biotechnology company focused on engineered proteins and respiratory disease before its strategic decline and restructuring. Its platform centered on antibody-mimetic science and immunology.

Geographic Base and Sector Classification

Headquartered in Germany and listed on NASDAQ as an ADR before restructuring, Pieris sat in specialty biotechnology.

Business Model Characteristics

The business depended on platform validation, clinical data, and partnership progress to create value.

Position Within the Biotechnology Landscape

Pieris belongs to the historical biotech-restructuring category rather than the current live public-company set.

Future catalysts

  • Pieris is now mostly a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a fresh pipeline event. The market is watching what remains after the unwind.

Recent news

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    Frequently Asked Questions

    What is the current stock price of Palvella Therapeutics (PVLA)?

    Palvella Therapeutics (PVLA) most recently closed at 145.77 USD, a -0.55% move versus the previous session.

    What does Palvella Therapeutics do?

    Pieris was a biotechnology company focused on engineered proteins and respiratory disease before its strategic decline and restructuring. Its platform centered on antibody-mimetic science and immunology.

    On which exchange is PVLA stock listed?

    Palvella Therapeutics (PVLA) is associated with NASDAQ, Germany, Biopharma.

    What is Pieris?

    Pieris is now mostly a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a fresh pipeline event.

    Which conditions is Palvella Therapeutics targeting with Pieris?

    Palvella Therapeutics is associated with immunology, respiratory disease based on its company overview and current catalyst commentary.

    How does Palvella Therapeutics describe recent progress with Pieris?

    Pieris is now mostly a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a fresh pipeline event.

    What future catalysts are investors watching for Palvella Therapeutics?

    Pieris is now mostly a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a fresh pipeline event. The market is watching what remains after the unwind.